ADEL-Y-04

ADEL-Y-04 is a preclinical **anti-Apolipoprotein E4 monoclonal antibody** being developed by **ADEL** for **Alzheimer's disease** and potentially **metabolic disease**. ApoE4 is a major genetic risk factor for Alzheimer's disease and is implicated in beta-amyloid accumulation, tau pathology, neuroinflammation, blood-brain barrier dysfunction, and altered lipid metabolism. ADEL-Y-04 is described by the sponsor as an ApoE4 antibody with high binding affinity for ApoE4 aggregates, and preclinical studies in ApoE4-expressing tauopathy models have shown reductions in pathological tau accumulation and synapse loss together with improvement in memory impairment. Public pipeline materials place the program at the **preclinical efficacy** stage, with later company reporting indicating plans to move into preclinical toxicology as part of timeline acceleration.